SCHEMBL16631241

SCHEMBL16631241

C#Cc1[nH]c(=O)cc(F)c1[C@@H]1O[C@H](CO)C(O)[C@@H]1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYNJ2 O15056 1/20 0.38
KDM4E B2RXH2 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MGAM O43451 1/20 0.37
GUSB P08236 1/20 0.37
MMP9 P14780 1/20 0.37
ALDH1A1 P00352 1/20 0.37
ALPI P09923 1/20 0.37
ALPG P10696 1/20 0.37
HPGD P15428 1/20 0.37
APEX1 P27695 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SLC5A2 P31639 4/20 0.36
SLC5A1 P13866 2/20 0.36
CYP1A2 P05177 2/20 0.36
GMNN O75496 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631175 0.91 CDA (0.35) SYNJ2KDM4ESLC5A2SLC5A1CYP1A2
SCHEMBL16631598 0.87 LGALS3 (0.35) SLC5A2LMNATSHRB4GALT1P2RY14
SCHEMBL16631255 0.86 SYNJ2 (0.39) SYNJ2KDM4EL3MBTL1MGAMGUSB
SCHEMBL16631823 0.83 SYNJ2 (0.42) SYNJ2KDM4EL3MBTL1MGAMGUSB
SCHEMBL16631826 0.81 SYNJ2 (0.46) SYNJ2KDM4EL3MBTL1MGAMGUSB
SCHEMBL18079909 0.77 SYNJ2 (0.38) SYNJ2KDM4EL3MBTL1MGAMGUSB
SCHEMBL18079916 0.77 CDA (0.34) SYNJ2LMNATSHRB4GALT1P2RY14
SCHEMBL18079908 0.76 SLC28A1 (0.43) KDM4ESLC5A2SLC5A1CYP1A2GMNN
SCHEMBL16631196 0.76 TSHR (0.33) LMNAMAPTPMP22SMN1; SMN2TSHR
SCHEMBL16631218 0.74 LGALS3 (0.35) SYNJ2SLC5A2LMNATSHRB4GALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 SYNJ2 642/4885KDM4E 4689/4885L3MBTL1 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.